Esperion Therapeutis.Inc. sell Northland Securities
Summary
This prediction ended on 17.03.24 with a price of €1.99. With a performance of 4.19%, the SELL prediction by Northland_Securities for Esperion Therapeutis.Inc. was trending in the wrong direction Northland_Securities has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | -29.735% | -29.735% | 57.881% |
iShares Core DAX® | -1.822% | -1.170% | 11.771% |
iShares Nasdaq 100 | -0.241% | 1.961% | 40.760% |
iShares Nikkei 225® | -2.310% | -1.758% | 21.493% |
iShares S&P 500 | -0.835% | 1.309% | 28.068% |
Comments by Northland_Securities for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.